ESR1 and cancer: Importantly, osteogenic niches within the bone microenvironment transiently reduce estrogen receptor (ER) expression in micrometastases of ER+ breast cancer cells via epigenomic reprogramming mediated by EZH2, facilitating endocrine resistance and enhanced cellular plasticity, which can potentially reactivate the dormant cancer cells [52].